LQDA Liquidia Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1819576 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY2,233.6%
TTM net income YoY192.7%
TTM EPS YoY178.2%
Revenue 3-yr CAGR193.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin37.4%
Net margin30.7%
FCF margin33.4%
EBITDA margin37.7%
Returns
ROE131.8%
ROA35.6%
ROIC (approx.)—
Asset turnover1.16x
Leverage & solvency
Liabilities / assets62.6%
Debt / equity0.00x
Current ratio2.31x
Interest coverage6.33x
Cash quality & payout
Operating cash flow / net income1.21x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $158.32M | $14.00M |
| Cost of revenue | — | $5.88M |
| Gross profit | — | $8.12M |
| R&D expense | $39.28M | $47.84M |
| SG&A expense | $157.18M | $81.57M |
| Operating income | -$51.38M | -$121.29M |
| Interest expense | $24.17M | $14.65M |
| Income tax | $0 | $0 |
| Net income | -$68.92M | -$128.29M |
| EBITDA | -$49.85M | -$119.10M |
| EPS (basic) | -0.80 | -1.63 |
| EPS (diluted) | -0.80 | -1.63 |
| Weighted avg. shares (diluted) | 86.06M | 78.71M |
| Balance sheet | ||
| Cash & equivalents | $190.68M | $176.48M |
| Receivables | $54.09M | $2.72M |
| Inventory | $23.80M | $241,000 |
| Current assets | $273.40M | $185.10M |
| PP&E, net | $11.84M | $8.30M |
| Goodwill | $3.90M | $3.90M |
| Intangibles | $2.95M | $3.16M |
| Total assets | $327.93M | $230.31M |
| Current liabilities | $135.77M | $41.78M |
| Total liabilities | $283.19M | $150.94M |
| Shareholders' equity | $44.75M | $79.38M |
| Shares outstanding | 87.20M | 84.68M |
| Cash flow statement | ||
| Operating cash flow | -$35.69M | -$93.42M |
| Capital expenditure | $4.34M | $4.95M |
| Free cash flow | -$40.02M | -$98.37M |
| Investing cash flow | -$6.34M | -$8.44M |
| Financing cash flow | $59.73M | $194.66M |
| Depreciation & amortization | $1.53M | $2.20M |
| Stock-based compensation | $29.47M | $18.81M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.